Multicenter Randomized Study to Compare Induction Therapy With Polyclonal Antithymocytes Globulins (ATG) Versus Monoclonal Anti-IL2R Antibody (Daclizumab) in a Triple Drug Regimen in Renal Transplant Recipients With High Immunological Risk. (TAXI)

NCT00682292 Phase 3 COMPLETED

To compare renal allograft rejection rates during the first year among high-immunological risk recipients between patients who received either ATG or the anti-IL2R mAb daclizumab.

Details

Lead sponsor	University Hospital, Lille
Phase	Phase 3
Status	COMPLETED
Enrolment	227
Start date	2001-05
Completion	2006-11

Conditions

• Renal Transplantation

Interventions

• Thymoglobulin (ATG)
• Daclizumab

Primary outcomes

• Incidence of biopsy-proven acute allograft rejection during the first post-transplant year — acute rejection proved by graft biopsy

Countries

France